Literature DB >> 22531556

Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Daniel R Tonkin1, Alan Whitmore, Robert E Johnston, Mario Barro.   

Abstract

Replicon particles derived from Venezuelan equine encephalitis virus (VEE) are infectious non-propagating particles which act as a safe and potent systemic, mucosal, and cellular adjuvant when delivered with antigen. VEE and VEE replicon particles (VRP) can target multiple cell types including dendritic cells (DCs). The role of these cell types in VRP adjuvant activity has not been previously evaluated, and for these studies we focused on the contribution of DCs to the response to VRP. By analysis of VRP targeting in the draining lymph node, we found that VRP induced rapid recruitment of TNF-secreting monocyte-derived inflammatory dendritic cells. VRP preferentially infected these inflammatory DCs as well as classical DCs and macrophages, with less efficient infection of other cell types. DC depletion suggested that the interaction of VRP with classical DCs was required for recruitment of inflammatory DCs, induction of high levels of many cytokines, and for stable transport of VRP to the draining lymph node. Additionally, in vitro-infected DCs enhanced antigen-specific responses by CD4 and CD8 T cells. By transfer of VRP-infected DCs into mice we showed that these DCs generated an inflammatory state in the draining lymph node similar to that achieved by VRP injection. Most importantly, VRP-infected DCs were sufficient to establish robust adjuvant activity in mice comparable to that produced by VRP injection. These findings indicate that VRP infect, recruit and activate both classical and inflammatory DCs, and those DCs become mediators of the VRP adjuvant activity. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531556      PMCID: PMC3519277          DOI: 10.1016/j.vaccine.2012.04.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  66 in total

1.  Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo.

Authors:  G J Randolph; K Inaba; D F Robbiani; R M Steinman; W A Muller
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

Review 2.  Steady-state and inflammatory dendritic-cell development.

Authors:  Ken Shortman; Shalin H Naik
Journal:  Nat Rev Immunol       Date:  2006-12-15       Impact factor: 53.106

3.  Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.

Authors:  G H MacDonald; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Xiangyi Zhao; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region.

Authors:  L J White; J G Wang; N L Davis; R E Johnston
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.

Authors:  S Schultz-Cherry; J K Dybing; N L Davis; C Williamson; D L Suarez; R Johnston; M L Perdue
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

7.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

8.  Critical role of dendritic cells in mouse mammary tumor virus in vivo infection.

Authors:  Maria Cecilia Courreges; Dalia Burzyn; Irene Nepomnaschy; Isabel Piazzon; Susan R Ross
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

9.  Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells.

Authors:  Kevin P Nishimoto; Amanda K Laust; Kehui Wang; Kurt I Kamrud; Bolyn Hubby; Jonathan F Smith; Edward L Nelson
Journal:  Viral Immunol       Date:  2007       Impact factor: 2.257

10.  Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania.

Authors:  Beatriz León; María López-Bravo; Carlos Ardavín
Journal:  Immunity       Date:  2007-04-05       Impact factor: 31.745

View more
  11 in total

Review 1.  mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors:  Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-02-07       Impact factor: 11.454

2.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

3.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

4.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

5.  An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Authors:  Syed Muaz Khalil; Daniel R Tonkin; Andrew T Snead; Griffith D Parks; Robert E Johnston; Laura J White
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

6.  Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.

Authors:  Raphaël M Zellweger; Robyn Miller; William E Eddy; Laura J White; Robert E Johnston; Sujan Shresta
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

Review 7.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

8.  Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A.

Authors:  Anne Beall; Boyd Yount; Chun-Ming Lin; Yixuan Hou; Qiuhong Wang; Linda Saif; Ralph Baric
Journal:  mBio       Date:  2016-01-05       Impact factor: 7.867

9.  Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.

Authors:  Jincun Zhao; Jingxian Zhao; Ashutosh K Mangalam; Rudragouda Channappanavar; Craig Fett; David K Meyerholz; Sudhakar Agnihothram; Ralph S Baric; Chella S David; Stanley Perlman
Journal:  Immunity       Date:  2016-06-07       Impact factor: 31.745

10.  Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.

Authors:  Sudhakar Agnihothram; Vineet D Menachery; Boyd L Yount; Lisa C Lindesmith; Trevor Scobey; Alan Whitmore; Alexandra Schäfer; Mark T Heise; Ralph S Baric
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.